Panavance Therapeutics
  • Our Science
    • Pipeline
    • About GP-2250
  • About
    • About Panavance
    • Leadership
    • Board of Directors
    • Advisors & Collaborators
    • Contact Panavance
  • Resources
    • Publications
    • Brochures
    • Videos
    • Press Releases
    • Events
  • Participate

Let’s engage.

Metabolism-based GP-2250 in combination with gemcitabine as a novel approach to pancreatic cancer: A mouse xenograft study- in vitro and in vivo. MBC Cancer

April 13, 2022 / 0 Minute Read

panavance therapeutics

  • Our Science
  • About
  • Resources
  • Participate
  • LinkedIn
  • Twitter

+1.610.922.1910

Copyright © 2023 Panavance Therapeutics Inc.